Legend Biotech Corp (LEGN)
39.92
+0.57
(+1.45%)
USD |
NASDAQ |
Nov 14, 16:00
39.92
0.00 (0.00%)
After-Hours: 18:13
Legend Biotech Enterprise Value: 6.251B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 6.251B |
| November 12, 2024 | 6.404B |
| November 11, 2024 | 6.379B |
| November 08, 2024 | 6.377B |
| November 07, 2024 | 6.546B |
| November 06, 2024 | 6.627B |
| November 05, 2024 | 7.223B |
| November 04, 2024 | 7.037B |
| November 01, 2024 | 7.175B |
| October 31, 2024 | 7.296B |
| October 30, 2024 | 7.158B |
| October 29, 2024 | 7.377B |
| October 28, 2024 | 7.348B |
| October 25, 2024 | 7.245B |
| October 24, 2024 | 7.119B |
| October 23, 2024 | 7.099B |
| October 22, 2024 | 7.299B |
| October 21, 2024 | 7.007B |
| October 18, 2024 | 6.900B |
| October 17, 2024 | 6.941B |
| October 16, 2024 | 7.112B |
| October 15, 2024 | 7.276B |
| October 14, 2024 | 8.155B |
| October 11, 2024 | 8.214B |
| October 10, 2024 | 8.262B |
| Date | Value |
|---|---|
| October 09, 2024 | 8.000B |
| October 08, 2024 | 7.857B |
| October 07, 2024 | 8.137B |
| October 04, 2024 | 8.043B |
| October 03, 2024 | 7.807B |
| October 02, 2024 | 7.971B |
| October 01, 2024 | 7.750B |
| September 30, 2024 | 7.980B |
| September 27, 2024 | 8.080B |
| September 26, 2024 | 7.634B |
| September 25, 2024 | 7.025B |
| September 24, 2024 | 7.341B |
| September 23, 2024 | 7.462B |
| September 20, 2024 | 7.943B |
| September 19, 2024 | 8.367B |
| September 18, 2024 | 8.198B |
| September 17, 2024 | 8.430B |
| September 16, 2024 | 8.395B |
| September 13, 2024 | 8.215B |
| September 12, 2024 | 8.290B |
| September 11, 2024 | 8.112B |
| September 10, 2024 | 8.122B |
| September 09, 2024 | 8.224B |
| September 06, 2024 | 7.845B |
| September 05, 2024 | 8.900B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.627B
Minimum
Mar 04 2021
12.94B
Maximum
Jun 22 2023
6.953B
Average
6.894B
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 384.40B |
| Alnylam Pharmaceuticals Inc | 32.35B |
| BioCryst Pharmaceuticals Inc | 2.050B |
| Biomarin Pharmaceutical Inc | 12.37B |
| National Healthcare Corp | 1.906B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.20M |
| Revenue (Quarterly) | 186.52M |
| Total Expenses (Quarterly) | 228.07M |
| EPS Diluted (Quarterly) | -0.10 |
| Gross Profit Margin (Quarterly) | 72.95% |
| Profit Margin (Quarterly) | -9.76% |
| Earnings Yield | -3.86% |
| Normalized Earnings Yield | -4.520 |